166
Participants
Start Date
December 7, 2020
Primary Completion Date
March 30, 2023
Study Completion Date
March 30, 2023
Durvalumab plus chemotherapy
"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
Research Site, Dalian
Research Site, Changchun
Research Site, Haerbin
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Wuxi
Research Site, Jiangyin
Research Site, Huai'an
Research Site, Yangzhou
Research Site, Hefei
Research Site, Jinan
Research Site, Qingdao
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Ningbo
Research Site, Taizhou
Research Site, Jinhua
Research Site, Dongyang
Research Site, Whenzhou
Research Site, Nanchang
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangdong
Research Site, Guangzhou
Research Site, Shenzhen
Research Site, Chengdu
Research Site, Baoding
Lead Sponsor
AstraZeneca
INDUSTRY